Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.34 |
| ▸ | CPB1 | P15086 | 1/20 | 0.34 |
| ▸ | QPCT | Q16769 | 3/20 | 0.33 |
| ▸ | KDM5A | P29375 | 3/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.30 |
| ▸ | ALPL | P05186 | 1/20 | 0.30 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18886405 | 0.84 | SMN1; SMN2 (0.37) | CPB2CPB1QPCTKDM2B | |
| SCHEMBL584619 | 0.78 | CA12 (0.41) | — | |
| SCHEMBL2841442 | 0.75 | PDE10A (0.46) | KDM5AKDM5B | |
| SCHEMBL23320277 | 0.75 | TBXAS1 (0.42) | CPB2CPB1 | |
| SCHEMBL4900683 | 0.74 | CPB2 (0.34) | CPB2CPB1KDM5AKDM5B | |
| SCHEMBL16828766 | 0.73 | ALDH1A1 (0.42) | TAAR1ALPLPLAA | |
| SCHEMBL31285260 | 0.72 | — | — | |
| SCHEMBL12229237 | 0.71 | CPB2 (0.32) | CPB2CPB1KDM5AKDM5B | |
| SCHEMBL20566564 | 0.71 | ALPL (0.43) | CPB2QPCTALPLPLAA | |
| SCHEMBL21404432 | 0.70 | CREBBP (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230008047-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-01-12 | — | — | US | disclosed |
| US-11058688-B2 | Imidazopiperazine inhibitors of transcription activating proteins | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-07-13 | — | — | US | disclosed |
| EP-3773587-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | Board of Regents, The University of Texas System (US) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019191667-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-10-03 | — | — | WO | disclosed |
| US-20190298729-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11058688-B2 | Imidazopiperazine inhibitors of transcription activating proteins | EP300, CREBBP, RBBP7 | CPB2 2372/4885CPB1 2392/4885QPCT 2834/4885 |
| US-20230008047-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | EP300, CREBBP, RBBP7 | CPB2 2372/4885CPB1 2392/4885QPCT 2834/4885 |
| US-20190298729-A1 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | EP300, CREBBP, RBBP7 | CPB2 2372/4885CPB1 2392/4885QPCT 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.